Barts Cancer Centre
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
Barts Cancer Centre
Jun 26, 2024, 13:51 |
Insight
Tom Powles: Durvalumab with neoadjuvant chemo then cystectomy in MIBC
Tom Powles shared on X: "Positive results from the NIAGARA Phase III trial showed durvalumab…
Jun 26, 2024, 08:30 |
Insight
IMFINZI (durvalumab) showed improved EFS and OS for MIBC in NIAGARA Phase III trial
First immunotherapy regimen before and after surgery to extend survival in bladder cancer Positive high-level results…
Feb 1, 2024, 15:42 |
Opinion
Thomas Powles: Enfortumab Vedotin and Pembrolizumab shows broad spectrum of activity for Regional Recurrence, Progression-free survival and Overall Survival in all subgroups
Jan 31, 2024, 15:42 |
Blog
Thomas Powles: We need better biomarkers in Urothelial Carcinoma
Thomas Powles, Director of Barts Cancer Centre, shared a post on X/Twitter: "Microsatellite instability (MSIH)…
Dec 23, 2023, 03:46 |
Blog
Barts Health NHS Trust: Tom Powles features in Nature’s 10
Barts Health NHS Trust shared on LinkedIn: “A Barts Health doctor whose research has helped…
Oct 23, 2023, 15:26 |
Insight
Tom Powles: Enfortumab vedotin and Pembrolizumab improving PFS and OS by 55% and 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%)
Tom Powles, Director of Barts Cancer Centre, shared on Twitter: "Enfortumab vedotin and Pembrolizumab improving…
Oct 15, 2023, 15:11 |
Insight
Aruni Ghose: We did not identify differences in the management or short-term outcomes of patients with OPSCC treated at Barts Cancer Centre before and during the COVID-19 pandemic
All:
7
Posts:
1 - 10
Eliot Levitt: The Yvonne Awards demonstrate something that it doesn't hurt to be reminded of
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Zainab Shinkafi-Bagudu's latest commentary on Cervical Cancer Elimination Forum
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Learn more about overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube